Medincell Execs to Present at Two U.S. Biotech Conferences in June
Event summary
- Medincell CEO Christophe Douat and CSO Grace Kim to present at Jefferies NY Biotech Conference on June 4, 2026.
- Same executives to participate in Evercore Summer Symposium in Newport, RI, June 22-24, 2026.
- Medincell's UZEDY® (risperidone LAI) approved in U.S., Canada, and South Korea for schizophrenia; bipolar I approval in U.S. in October 2025.
- Teva submitted NDA for olanzapine LAI in December 2025; FDA accepted for review in February 2026.
- Company employs 140+ people across 25 nationalities.
The big picture
Medincell's participation in high-profile U.S. biotech conferences underscores its shift from clinical-stage to commercial-stage player. The company's BEPO® technology platform, now with FDA-approved products, positions it as a key player in long-acting injectables. Success hinges on Teva's commercial execution and Medincell's ability to advance its investigational pipeline.
What we're watching
- Pipeline Progress
- Whether Medincell can sustain momentum from UZEDY® success with olanzapine LAI approval timeline.
- Partnership Dynamics
- How Teva's commercialization of Medincell's products will impact revenue sharing and future collaborations.
- Investor Sentiment
- The pace at which investor interest translates into valuation changes post-conference presentations.
Related topics